Phase 2 Lupus Trial, Recruiting NCT06625671 Sponsor: DualityBio Inc. Condition: Lupus
Back to Lupus

Phase 2 Lupus Trial, Recruiting

NCT06625671
Recruiting Phase 2 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Part A (Healthy Volunteers):

  • You fully understand what the study involves and are willing to sign a consent form to participate
  • You are a healthy man or woman between 18 and 55 years old, and your body weight falls within an acceptable range for your height (confirm with trial site for exact BMI limits)
  • You have no significant health problems based on a doctor's review of your medical history, physical exam, blood tests, and heart tracing (ECG)
  • You agree to use reliable birth control during the study (applies to women who could become pregnant and to men)
  • You are willing and able to follow all the study requirements and attend all appointments

Part B (Patients with Lupus):

  • You fully understand what the study involves and are willing to sign a consent form to participate
  • You are a man or woman between 18 and 70 years old
  • You have been on a stable treatment plan for your lupus for at least 1 month before joining the study
  • You have been diagnosed with Systemic Lupus Erythematosus (SLE) according to recognised medical guidelines, AND have had a positive lupus blood test (ANA or anti-dsDNA), AND currently have active lupus affecting your skin
  • OR you have been diagnosed with Cutaneous Lupus Erythematosus (CLE) confirmed by a skin biopsy, AND your skin lupus is still active despite trying standard treatments

Who may not be able to join:

Part A (Healthy Volunteers):

  • You have a history of any significant medical condition
  • You have had shingles, or you get recurring cold sores or genital herpes
  • You have had any active infection (bacterial, viral, fungal, or parasitic) in the 30 days before the study starts
  • You have a known allergy or sensitivity to any ingredient in the study drug (DB-2304)
  • You have had surgery in the past 3 months or plan to have surgery during the study

Part B (Patients with Lupus):

  • You currently have lupus affecting your kidneys, or you have moderate-to-severe or long-term kidney disease
  • You have had lupus affecting your brain or mental health within the 8 weeks before screening
  • You have another active skin condition or active joint disease (such as psoriasis or rheumatoid arthritis) that could interfere with how the study assessments are done
  • You have a current or past history of cancer, with some exceptions for certain skin cancers that were fully removed and considered cured more than 2 years ago (confirm with trial site)
  • You have a known condition that weakens your immune system, have had your spleen removed, or have any condition that makes you more prone to infections

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lily Hu, DualityBio Inc.

Phone: +86 13910863858

Australian sites

Site AUS01-0, Melbourne, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
DualityBio Inc.
Registry
ClinicalTrials.gov
Start date
4 October 2024
Est. completion
30 June 2027

Where this trial is recruiting

🇦🇺 Australia 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

TEAEs; SAEs; ECG parameters; Weight measurements; Heart Rate measurements; Pulse rate measurements; Respiratory rate measurements; Body temperature measurements

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov